Table 2.
Three-Year Incidence of Neurocognitive Diagnoses Among Patients With Systolic HF (ICD-10-CM: I50.2 or I50.4) Receiving Sacubitril/Valsartan vs Propensity Score-Matched Patients Receiving ACEIs or ARBs
| Sacubitril/Valsartan (n = 11,313)a |
ACEI/ARB (n = 11,313)a |
HR (95% CI) | P Value | |||
|---|---|---|---|---|---|---|
| Events | 3-y K-M Estimate | Events | 3-y K-M Estimate | |||
| Primary endpoint | 858 | 10.7% | 1,209 | 15.0% | 0.69 (0.63-0.75) | <0.001 |
| Cognitive decline | 767 | 9.5% | 1,087 | 13.3% | 0.69 (0.63-0.76) | <0.001 |
| Dementia | 281 | 3.4% | 427 | 5.0% | 0.65 (0.57-0.77) | <0.001 |
| Alzheimer’s disease | 56 | 0.6% | 118 | 1.3% | 0.48 (0.35-0.66) | <0.001 |
ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; HF = heart failure; ICD-10-CM = International Classification of Diseases-10th Revision-Clinical Modification; K-M = Kaplan-Meier.
Patients with prevalent diagnoses of interest at baseline were excluded from calculation of incidence for each analysis. Outcomes were defined using the following ICD-10-CM codes: dementia (vascular dementia [F01], dementia in other diseases [F02], and unspecified dementia [F03]), Alzheimer’s disease [G30], cognitive decline (other symptoms and signs involving cognitive functions and awareness, R41.8]). The primary endpoint was defined as the composite (first occurrence) of any of these diagnoses.